ViaCyte is developing cell therapies to replace lost beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially matured…
Cancer is a leading cause of death in California. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). A team at UCSD is testing an antibody therapy…
ViaCyte is developing cell therapies to replace lost pancreatic beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially…
To help improve accessibility to eligible CIRM patients This project will allow patients in underserved communities in California equal access to clinical trials without bias due to financial circumstances.
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
